RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins

Cancer Research

Volumn 61, Issue 23, 2001, Pages 8470-8479

  Ansardi, David C ^a   Porter, Donna C ^a   Jackson, Cheryl A ^b   Gillespie, G Yancey ^c   Morrow, Casey D ^d  

^a Replicon Technologies   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS DNA; VIRUS RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GRAFT; CANCER SURVIVAL; CYTOPATHOGENIC EFFECT; DRUG EFFECT; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFECTIOUS COMPLICATION; METASTASIS; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REPLICON; TUMOR CELL; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CYTOPATHOGENIC EFFECT, VIRAL; GLIOMA; HELA CELLS; HUMANS; MICE; MICE, SCID; NEOPLASMS; POLIOVIRUS; REPLICON; RNA, VIRAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035576889     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Treatment of human cancer with mumps virus
2. Viruses with oncolytic properties and their adaptation to tumors
3. Present status of oncolytic virus studies
4. Viruses as an aid to cancer therapy: Regression of solid and ascites tumors in rodents after treatment with bovine enterovirus
5. Newcastle disease virus as an antineoplastic agent
6. A Phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate
7. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
8. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy
9. Newcastle disease virus selectively kills human tumor cells
10. Studies on the use of viruses in the treatment of carcinoma of the cervix
11. Gene therapy for cancer: What have we done and where are we going?
12. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
13. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus
14. Gene therapy for glioblastoma in adult patients: Safety and efficacy evaluation of an in situ injection of recombinant retroviruses producing cells carrying the thymidine kinase gene of the herpes simplex type 1 virus, to be followed with the administration of ganciclovir
15. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
16. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors
17. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene
18. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
19. Tumors expressing the cytosine deaminase gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor
20. Characterization of poliovirus replicons encoding carcinoembryonic antigen
21. Targeted foreign gene expression in spinal cord neurons using poliovirus replicons
22. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene using a complementation system which provides the P1 capsid protein in trans
23. Demonstration of the specificity of poliovirus encapsidation using a novel replicon which encodes enzymatically active firefly luciferase
24. Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type I Gag
25. Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides P1 capsid precursor in trans
26. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily
27. Identification, and characterization of the cis-acting elements of the human CD155 gene core promoter
28. Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene
29. Intergeneric poliovirus recombinants for the treatment of malignant glioma
30. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system; implications for the pathogenesis of poliomyelitis
31. Cytokine production in motor neurons by poliovirus replicon vector gene delivery
32. Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis
33. Foot-and-mouth disease virus 2A protease mediates cleavage in attenuated Sabin 3 poliovirus vectors engineered for delivery of foreign antigens
34. Encapsidation of genetically engineered poliovirus mini-replicons which express HIV-1 gag and pol proteins upon infection
35. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
36. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
37. Overexpression of the CD155 gene in human colorectal carcinoma
38. Poliovirus infection induces apoptosis in CaCo-2 cells
39. Poliovirus induces apoptosis in the mouse central nervous system
40. Apoptosis-inducing and apoptosis-preventing functions of poliovirus
41. Poliovirus protease 3C(pro) kills cells by apoptosis
42. Poliovirus 2A protease induces apoptotic cell death
43. Characterization of mouse lines transgenic with the human poliovirus receptor gene
44. Transgenic mice expressing a human poliovirus receptor: A new model for poliomyelitis
45. Poliomyelitis in intraspinally inoculated poliovirus receptor transgenic mice
46. Poliovirus spreads from muscle to the central nervous system by neural pathways
47. Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor
48. Current diagnosis and treatment of leptomeningeal metastasis
49. Leptomeningeal cancer in leukemia and solid tumors
50. Prophylaxis and treatment of leptomeningeal carcinomatosis in solid tumors of adulthood
51. The role of radiation therapy in the treatment of brain metastases
52. Intracranial metastases from systemic cancer
53. Management of brain metastases
54. The Mouse Brain Library @www.mbl.org